Substantial changes included: ● Revised efficacy variables to reflect updated scientific approach and statistical analyses ● Inclusion Criteria No. 3 and throughout protocol: changed "active" to active "inflammatory" chorioretinal and/or "inflammatory" retinal vascular lesion ● Increase the maximum allowable stable dose for an inactive uveitis patient to include up to 35 mg. ● Exclusion Criteria No. 9: changed BCVA worse than 20/400 to 20/200 and logMar from "> 1.34" to "> 1.0" ● Exclusion Criteria No. 10: added "All subjects with intermediate uveitis must have had a prior brain magnetic resonance imaging (MRI) at time of or after diagnosis of intermediate uveitis" ● Exclusion Criteria No. 14: changed dose of mycophenolate mofetil from ≤ 2 "mg" to ≤ 2 "gm" ● Concomitant Therapy: added text regarding concomitant and prohibited therapies to provide additional clarification regarding the use of topical or systemic corticosteroids ● Japan Sub-study: added active Hepatitis C and positive or indeterminate β-D-glucan as an exclusion criteria ● Japan Sub-study: Analysis of Efficacy: removed the following sentence: "An additional analysis the Time to Treatment Failure will be compared between the adalimumab group and the placebo group in the Japan ITT dataset using a log-rank test" as agreed upon with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), the primary analysis will be performed on the integrated ITT dataset and a statistical test to compare the treatment groups in the Japan ITT dataset is not necessary.

Substantial changes included: ● Best Corrected Visual Acuity Testing: Removed the requirement that the individual performing refraction and BCVA testing not be the Principal Investigator or the same person entering data on the eCRFs based on updated visual acuity requirements. ● Handling/Processing of Samples: added "Blood samples for Adalimumab and anti-adalimumab antibody (AAA) analysis will be collected by venipuncture into appropriately labeled evacuated serum collection tubes without gel separator at the required visits. Blood samples for Adalimumab analysis will also be obtained if a subject is discontinued from the study. Sufficient blood will be collected to provide approximately 1 mL serum. Allow the blood to clot for 30 minutes at room temperature before centrifugation." ● Collection of Samples for Analysis: Revised the number of pharmacokinetic (PK) and AAA samples that will be collected.

Substantial changes included: ● Inclusion Criterion No. 5 – Revised sentence to read "Subject must have a history of experiencing a disease flare while tapering off their oral corticosteroid therapy within the past 18 months" to provide correct interpretation of the appropriate subject population to be included. ● Efficacy Variables – Removed "3 lines" throughout the protocol when assessing Best Corrected Visual Acuity to provide clarification that worsening of BCVA will be based on the number of letters. ● Added text to indicate that information collected on AC cell count/grade would not only be a component of the primary endpoint but also be evaluated as a secondary efficacy variable. ● Exclusion Criterion No. 2: Added Human T Lymphotropic Virus Type 1 (HTLV-1) infection, Whipple's disease and HZV (herpes zoster virus). ● Prohibited Therapy: Added "anti-vascular endothelial growth factor (VEGF) therapy" and "periocular, intraocular or intravitreal injections."

Substantial changes included: Inclusion Criterion: ● Added requirement for ≥10 mg oral prednisone for 90 days prior to Baseline ● Added option to use QuantiFERON®-TB Gold for TB screening ● Removed text requiring reading of purified protein derivative (PPD) test at study site and added text indicating TB screening tests are performed locally and annually ● Added instruction for TB prophylaxis ● Added instruction that subjects with documented completion of Center for Disease Control (CDC) recommended prophylaxis may conditionally be permitted to enroll ● Added increase of screening period up to 45 days if a subject is required to receive ≥ 28 days of TB prophylaxis Exclusion Criteria: ● Exclude subjects with 1 immunosuppressive therapy with dose that has not been stable for at least 28 days or who are on a dose outside of the allowed range listed ● Exclude subjects with macular edema due to diabetic retinopathy ● Changed description of demyelinating disease ● Expanded and clarified description of exclusionary infections ● Clarified that subjects with an active systemic viral infection or any active viral infection are excluded ● Added exclusion criterion that allows the prior use of intravitreal anti-VEGF therapy provided a 3 month washout period from Baseline is observed ● Added Ozurdex® (dexamethasone implant) and intravitreal methotrexate as prohibited therapy ● Exclude marijuana use including medical marijuana in the previous 12 months ● Exclude hepatitis B surface antigen positive subjects ● Removed requirement that Screening visit fundus photo is evaluated prior to the Baseline visit Removed central reader's precedence if assessment differs from investigator's assessment ● Added diagnosis of lupus like syndrome, multiple sclerosis or demyelinating disease and non-compliance with TB therapy as discontinuation criteria ● Added criteria that age-related eye disease study (AREDS) classification does not apply to subjects with pseudophakia

Substantial changes included: ● Clarified that methotrexate, cyclosporine, mycophenolate mofetil or azathioprine cannot be discontinued within 28 days prior to the Baseline visit.

Substantial Changes included: ● Added text to exclude use of systemic carbonic anhydrase inhibitor within 1 week prior to Screening visit and as prohibited therapy. ● Provided details of the nature of syphilis confirmatory testing. ● Added instruction to evaluate subjects for treatment failure criteria at Unscheduled visits (as applicable) and complete Unscheduled visit activities per the investigator's clinical judgment. ● Added instruction to use the same fundus camera throughout the study per subject.

Substantial changes included: ● Changed period of inactive disease and minimum length of time the subject must be taking ≥ 10 mg of oral prednisone to 28 days prior to Baseline ● Removed allowance for subjects with positive TB tests except if a subject received Bacille Calmette-Guérin (BCG) vaccination or has history of an ulcerative reaction to a PPD skin test. If the PPD test is positive, the QuantiFERON®-TB Gold test must be performed. If the QuantiFERON®-TB Gold test is negative, the subject is eligible ● Added to criterion to require an MRI report completed within 90 days prior to Baseline to include a statement that reveals no hint of demyelinating disease such as multiple sclerosis for subjects who have intermediate uveitis or panuveitis that have signs of intermediate uveitis ● Clarified that immunosuppressive therapy including methotrexate, cyclosporine, mycophenolate mofetil or azathioprine should not be discontinued within 28 days prior to Baseline ● Modification to exclude subjects who received Retisert® within 3 years prior to Baseline or had complications related to the device. Added exclusion for those subjects who had Retisert® removed within 90 days prior to Baseline or complications related to device removal • Changed exclusion of subjects with macular edema due to diabetic retinopathy to subjects with clinically significant macular edema due to diabetic retinopathy ● Modified that both Fluorescent Treponemal Antibody (FTA) and Rapid Plasma Reagin (RPR) must be tested, and if positive the subject would be excluded ● Exclude subjects with macular edema as the only sign of uveitis ● Exclude subjects with a history of scleritis • Exclude subjects who require TB Prophylaxis • Added “any TB-prophylaxis therapy” and “Retisert®" to list of prohibited medications ● Dilated Indirect Ophthalmoscopy: Added instruction to record the number of lesions, the location(s), size(s) and whether the lesions are active or inactive with a retinal drawing

Substantial changes included: ● Clarified that at least one disease flare must occur within 18 months of Screening and that this flare has to occur during or up to a maximum of 28 days after tapering off the oral corticosteroid therapy. ● Revised language to include subjects with either negative PPD (< 5 mm of induration) or negative QuantiFERON®-TB Gold test (or Interferon-Gamma Release Assay [IGRA] equivalent) as eligible. Only 1 TB test is permitted to allow the subject in the study. Subjects with a repeat indeterminate QuantiFERON®-TB Gold test (or IGRA equivalent) result are not eligible. Added that subjects with "previous" TB are also not eligible for this study. ● Reduced the number of letters a subject must read for BCVA to 20 letters. ● Added tacrolimus as an acceptable concomitant immunosuppressant. ● Created Exclusion to allow prior use of cyclophosphamide provided a 30 day washout prior to Baseline is observed. Added chlorambucil and cyclophosphamide to prohibited concomitant medication list. ● Exclude subjects with cystoid macular edema unless the documented retinal changes are persistent, residual and stable as defined by the SUN criteria (persistent is > 3 months duration). ● Reduced intravitreal anti-VEGF therapy washout periods for Lucentis® (ranibizumab) or Avastin® (bevacizumab) to 45 days of Baseline or for anti-VEGF Trap (Aflibercept) for 60 days of Baseline. ● Changed to allow refractive laser surgery, retinal laser photocoagulation or neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy laser ≥ 30 days prior to Baseline visit.

● Ranked secondary variables. ● Added language and new requirements regarding malignancy in patients who are 30 years old or younger. ● Adverse Event Reporting changed to require non-serious events of malignancy in subjects 30 or younger to be reported to Abbvie within 24 hours of site awareness.

Substantial changes included: ● Removed interim analyses and reduced the total number of treatment failures to complete the study. ● Added Rituxan® (rituximab) as prohibited therapy. ● Added subjects with optic neuritis are exclusionary. ● Added Stelara® (ustekinumab), Benlysta® (belimumab), and corticosteroids with the exceptions of protocol specified prednisone taper and the protocol specified corticosteroid eyedrop taper as prohibited medications.

Substantial changes included: • Increase the number of Treatment Failures from currently planned 76 to approximately 96 to ensure approximately 80% statistical power.